Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).
To evaluate possible differences between patients with refractory duodenal ulcers and those with duodenal ulcers that respond to standard doses of antisecretory medications, we determined basal acid outputs by nasogastric suction and daily smoking histories in 75 patients with endoscopically documented active duodenal ulcers. Patients were treated for at least eight weeks with standard doses of antisecretory medications and endoscopic healing or nonhealing was documented. Fifty-five patients that had complete healing of their duodenal ulcers had a mean basal acid output of 6.6 +/- 5.3 meq/hr, and 18/55 had daily cigarette smoking histories, whereas 20 patients that had nonhealing duodenal ulcers had a mean basal acid output of 20.0 +/- 9.6 meq/hr, and 8/20 had daily cigarette smoking histories. There were no significant differences between the two groups with regard to age, duodenal ulcer size, or cigarette smoking history. However, there were significant differences in male-female ratio (P less than 0.02) and in mean basal acid output (P less than 0.001), and all patients with nonhealing duodenal ulcers had basal acid outputs of greater than 10.0 meq/hr. Patients with nonhealing duodenal ulcers were treated with increased doses of ranitidine, mean 675 mg/day (range 600-1200 mg/day), and all had complete healing endoscopically documented. These results indicate that patients treated with standard doses of antisecretory medications with nonhealing duodenal ulcers have increased basal acid outputs of greater than 10.0 meq/hr, and the duodenal ulcers heal with increased doses of antisecretory medication.
Collen
M J
MJ
Department of Medicine, Georgetown University Medical Center, Washington, DC 20007.
Stanczak
V J
VJ
Ciarleglio
C A
CA
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002927:Cimetidine / Q000008:administration & dosage / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015738:Famotidine; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use; D012907:Smoking / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D013844:Thiazoles; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine